Close

RedHill Biopharma (RDHL) Misses Q2 EPS by 4c

November 29, 2022 8:03 AM EST

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $23.19 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings